← Azimuth Daily
Capturing data…
Capturing data…
SAT, 7 NOV · 88 ITEMS
STAT News, Swissinfo · Science & Medicine
Novartis has disclosed six new, previously unreported cases of tumors in children who received , its for spinal muscular atrophy (SMA). This disclosure adds to a known safety concern surrounding the therapy's delivery system, which has previously been linked to cancer risks in animal studies and a small number of patient cases. The total number of reported tumor cases following Zolgensma treatment is now higher, intensifying the regulatory and medical scrutiny of the treatment's long-term risks.
The claim is well-grounded, originating from a formal disclosure by Novartis itself and reported by STAT News, a reputable secondary source. The exact number of new cases is reported as 'six more' in the highlight and grounding, while some search snippets mention 'seven', but the core fact of a new disclosure of multiple tumor cases is consistent across sources.
This is genuinely new reporting, based on a disclosure made in early November 2026, with no indication that the underlying material is a resurfacing of older data.